Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Adaptimmune Therapeutics (NASDAQ: ADAP) has announced its participation in three major scientific conferences: SITC (November 6-10, Houston), CTOS (November 13-16, San Diego), and ASH (December 7-10, San Diego). The company will present research on cell therapies for solid tumors, particularly focusing on synovial sarcoma treatments.
Key presentations include data on afami-cel's anti-tumor activity, the IGNYTE-ESO trial results, and decentralized manufacturing processes. A notable virtual event is scheduled for November 18, featuring Dr. Sandra D'Angelo from Memorial Sloan Kettering Cancer Center, discussing the IGNYTE-ESO dataset and engineered cell therapies' impact on sarcoma treatment.
Adaptimmune Therapeutics (NASDAQ: ADAP) ha annunciato la sua partecipazione a tre importanti conferenze scientifiche: SITC (6-10 novembre, Houston), CTOS (13-16 novembre, San Diego) e ASH (7-10 dicembre, San Diego). L'azienda presenterà ricerche sulle terapie cellulari per i tumori solidi, con particolare attenzione ai trattamenti per il sarcoma sinoviale.
Le presentazioni chiave includono dati sull'attività antitumorale di afami-cel, i risultati dello studio IGNYTE-ESO e i processi di produzione decentralizzata. Un evento virtuale notevole è programmato per il 18 novembre, con la Dr.ssa Sandra D'Angelo del Memorial Sloan Kettering Cancer Center, che discuterà il dataset IGNYTE-ESO e l'impatto delle terapie cellulari ingegnerizzate sul trattamento del sarcoma.
Adaptimmune Therapeutics (NASDAQ: ADAP) ha anunciado su participación en tres importantes conferencias científicas: SITC (6-10 de noviembre, Houston), CTOS (13-16 de noviembre, San Diego) y ASH (7-10 de diciembre, San Diego). La compañía presentará investigaciones sobre terapias celulares para tumores sólidos, centrándose especialmente en tratamientos para el sarcoma sinovial.
Las presentaciones clave incluirán datos sobre la actividad antitumoral de afami-cel, los resultados del ensayo IGNYTE-ESO y procesos de fabricación descentralizada. Un evento virtual notable está programado para el 18 de noviembre, con la Dra. Sandra D'Angelo del Memorial Sloan Kettering Cancer Center, quien discutirá el conjunto de datos IGNYTE-ESO y el impacto de las terapias celulares ingenierizadas en el tratamiento del sarcoma.
Adaptimmune Therapeutics (NASDAQ: ADAP)는 세 가지 주요 과학 회의에 참가한다고 발표했습니다: SITC (11월 6-10일, 휴스턴), CTOS (11월 13-16일, 샌디에고), ASH (12월 7-10일, 샌디에고). 이 회사는 고형 종양에 대한 세포 치료 연구를 발표할 예정이며, 특히 활막 연조직 종양 치료에 중점을 둡니다.
주요 발표 사항에는 afami-cel의 항종양 활성이 포함된 데이터, IGNYTE-ESO 시험의 결과 및 분산 제조 공정이 포함됩니다. 주목할만한 온라인 이벤트는 11월 18일에 예정되어 있으며, 메모리얼 슬론 케터링 암 센터의 Dr. Sandra D'Angelo가 IGNYTE-ESO 데이터 세트와 세포 치료의 효과에 대해 논의할 예정입니다.
Adaptimmune Therapeutics (NASDAQ: ADAP) a annoncé sa participation à trois grandes conférences scientifiques : SITC (du 6 au 10 novembre, Houston), CTOS (du 13 au 16 novembre, San Diego) et ASH (du 7 au 10 décembre, San Diego). L'entreprise présentera des recherches sur les thérapies cellulaires pour les tumeurs solides, en mettant particulièrement l'accent sur les traitements du sarcome synovial.
Les présentations clés incluent des données sur l'activité anti-tumorale de l'afami-cel, les résultats de l'essai IGNYTE-ESO et les processus de fabrication décentralisée. Un événement virtuel notable est prévu pour le 18 novembre, mettant en vedette Dr. Sandra D'Angelo du Memorial Sloan Kettering Cancer Center, qui discutera du jeu de données IGNYTE-ESO et de l'impact des thérapies cellulaires ingénierées sur le traitement du sarcome.
Adaptimmune Therapeutics (NASDAQ: ADAP) hat seine Teilnahme an drei wichtigen wissenschaftlichen Konferenzen angekündigt: SITC (6.-10. November, Houston), CTOS (13.-16. November, San Diego) und ASH (7.-10. Dezember, San Diego). Das Unternehmen wird Forschung zu Zelltherapien für solide Tumoren präsentieren, insbesondere mit Fokus auf Behandlungen von synovialem Sarkom.
Schlüsselpräsentationen umfassen Daten zur antitumoralen Aktivität von afami-cel, die Ergebnisse der IGNYTE-ESO-Studie und dezentrale Herstellungsverfahren. Eine bemerkenswerte virtuelle Veranstaltung ist für den 18. November geplant, bei der Dr. Sandra D'Angelo vom Memorial Sloan Kettering Cancer Center über den IGNYTE-ESO-Datensatz und die Auswirkungen von ingenieurgemachten Zelltherapien auf die Sarkombehandlung sprechen wird.
- None.
- None.
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced presence and presentations at key scientific and medical conferences in November and December.
- Society for Immunotherapy of Cancer (SITC) 39th annual meeting, November 6-10, Houston, TX
- Podium presentation: "Delivering on the Promise of Cell Therapies for Solid Tumors: T-cell Therapy for Synovial Sarcoma" / Jo Brewer, PhD, Chief Scientific Officer, Adaptimmune. Scheduled for November 8, 1:45-3:20 PM CST, Session 106d: Biotech Breakthroughs – Solid Tumor IO at the Tipping Point.
- Podium presentation: "Translational analyses reveal mechanisms of afami-cel's anti-tumor activity in synovial sarcoma" / Mihaela Druta, MD, Vice Chair, Sarcoma Center, Moffitt Cancer Center. Scheduled for November 8, 3:50 PM – 5:25 PM CST, Oral Abstract Session 1.
- Connective Tissue Oncology Society (CTOS) 2024 annual meeting, November 13-16, San Diego, CA
- Podium presentation: "Planned Analysis of the Pivotal IGNYTE-ESO Trial of Lete-Cel in Patients with Synovial Sarcoma or Myxoid/Round Cell Liposarcoma" / Sandra D'Angelo, M.D., Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center. Scheduled for Saturday, November 16, 10:30 AM – 12:00 PM PST, Session 12: Immunology.
- Encore podium presentation: "Translational analyses reveal mechanisms of afami-cel's anti-tumor activity in synovial sarcoma" / Mihaela Druta, M.D., Vice Chair, Sarcoma Center, Moffitt Cancer Center. Scheduled for Saturday, November 16 10:30 AM – 12:00 PM PST, Session 12: Immunology.
- Encore poster presentation: "Impact of afami-cel on the health state of patients with advanced SyS or MRCLS: cohort 1 of SPEARHEAD-1" / Michael Wagner, M.D., Sarcoma Medical Oncologist, Dana-Farber Cancer Institute. Scheduled for Thursday, November 14, Friday, November 15, and Saturday, November 16, poster sessions 10:00 - 10:30 AM and 3:00-3:30 PM PST.
- Sponsored symposium: TECELRA® (afamitresgene autoleucel;'afami-cel') Cell Therapy for Treatment of Eligible Adults with MAGE-A4+ Synovial Sarcoma. Hosted by Sandra D'Angelo, M.D., Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center. Scheduled for Thursday, November 14th, 6:30 PM PST.
- Adaptimmune will host a virtual event to discuss and review the IGNYTE-ESO dataset and the impact of engineered cell therapies on the treatment landscape in sarcoma. The event will feature Sandra D'Angelo, M.D., Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center, an investigative clinician in both the SPEARHEAD and IGNYTE-ESO clinical trials, author and presenter of the IGNYTE-ESO data update at CTOS. A live question and answer session will follow the formal presentation. The virtual event will take place on Monday, November 18, 2024 from 2:30 PM ET to 3:30 PM ET. To register, click here.
- American Society of Hematology (ASH) 66th Annual Meeting, December 7-10, San Diego, CA
- Poster presentation: "Preclinical Proof of Concept for Decentralized Manufacturing of a MAGE-A4/CD8α-Expressing Autologous T-Cell Therapy for Solid Tumors" / Melissa Herman, PhD., Associate Director – Pipeline Research, Adaptimmune (with Galapagos). Scheduled for Saturday, December 7, 2024, 5:30 – 7:30 PM PST.
About Adaptimmune
Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
T : +1 215 825 9310
M : +1 215 460 8920
Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228843
FAQ
What conferences will Adaptimmune (ADAP) attend in November and December 2024?
What is the focus of Adaptimmune's IGNYTE-ESO trial presentation at CTOS 2024?
When is Adaptimmune's virtual event discussing the IGNYTE-ESO dataset scheduled?
What will be presented at ASH 2024 regarding Adaptimmune's manufacturing process?
